N/A N=353 Rheumatoid Arthritis: Comparison of Active Therapies in Patients With Active Disease Despite Methotrexate Therapy
Rheumatoid Arthritis
Primary: Mean 48-week Change in DAS28 — -2.12; -2.29 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=210 Moderate Rheumatoid Arthritis (RA) With Etanercept (Enbrel)
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Low Disease Activity at Week 12 — 21.2; 33.0 percentage of participants — p=0.055
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 3 N=25 Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: 12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score — 11.4 units on a scale — p=<0.01
Phase 3 N=194 Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Rheumatoid Arthritis
Primary: Clinical Disease Activity Index (CDAI) Remission (≤2.8) at Both Week 20 and Week 24 — 18.8; 6.1 percentage of subjects
Phase 4 N=9 Ticagrelor in Methotrexate-Resistant Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score for 28-joint Counts (DAS28) — 5.7; 4.3 score on a scale
N/A N=178 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis · Psoriatic Arthritis · Periodontal Disease
Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants
N/A N=24 Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk
Rheumatoid Arthritis
Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05
Phase 4 N=63 Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of CD27+ Switched Memory B Cells at Week 12 — 13.2; 13.8 Percentage of B Cells — p=0.3
N/A N=18 Ultrasound Efficacy in Moderate Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Low Synovitis Scores — 1 Participants
Phase 2 N=39 Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Change From Baseline in Target Engagement Biomarkers- Soluble Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) Complexed to GSK3196165 — 0.972; 13.799; 0.960…
Phase 4 N=27 IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA
Rheumatoid Arthritis
Primary: IL-7 and IL-7R Expression in Peripheral Blood Mononuclear Cells of RA Patients With Active vs. Inactive Disease Treated With DMARD and/or CIMZIA. — 0.700; 1.330; 0.777…
Phase 4 N=203 RESTART C0168Z05 Rheumatoid Arthritis Study
Rheumatoid Arthritis
Primary: Percent of Patients Who Achieved a EULAR (The European League Against Rheumatism) Response at Week 10 — 49.7 Percentage
N/A N=79 Living Well With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04
N/A N=462 Physical Activity in Patients With Rheumatoid Arthritis Treated With Adalimumab in Routine Clinical Practice
Rheumatoid Arthritis
Primary: Mean Change From Baseline in Total Physical Activity Short Questionnaire to Assess Health-enhancing Physical Activity (SQUASH) Score — 870.0 units on a scale
Phase 3 N=511 Remission and Joint Damage Progression in Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants in DAS 28 C-reactive Protein (CRP) Remission at Month 12 — 106; 59 participants — p=<0.001
Phase 4 N=234 An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants
Phase 2 N=254 Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis Patients
Rheumatoid Arthritis
Primary: ACR Efficacy Criteria — 63; 57; 57; 61 participants
Phase 2 N=105 A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
Rheumatoid Arthritis
Primary: Change in Clinical Disease Activity Index (CDAI) — 18; 17; 12 Participants
N/A N=224 Effects of a Rheumatoid Arthritis Self-management Program
Arthritis, Rheumatoid
Primary: Disease Activity — 3.38; 3.62 score on a scale
Phase 4 N=259 Safety and Effectiveness of Acthar Gel in Participants With Rheumatoid Arthritis
Arthritis, Rheumatoid
Primary: Part 1: Number of Participants With Low Disease Activity (LDA) by Visit — 0; 17; 37; 163 Participants — p==0.242
Phase 4 N=25 Rheumatoid Arthritis Memory B Cells and Abatacept
Rheumatoid Arthritis
Primary: CDAI Score — 36.06 score on a scale
Phase 2 N=201 A Study of ARRY-438162 in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: American College of Rheumatology 20% (ACR20) Response Rate at Week 12 — 45.1; 58.0; 60.0; 54.0 percentage of participants
Phase 4 N=54 A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs
Rheumatoid Arthritis
Primary: Percent Change From Baseline to Week 12 in Synovitis Measured by Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic…
Phase 2 N=47 Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants Achieving DAS28 Remission. — 6; 6 Participants — p=0.530
Phase 4 N=10 A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Rheumatoid Arthritis
Primary: Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT) Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Synovitis Score — 3.4; 2.3…
Phase 2 N=158 A Study for Patients With Active Rheumatoid Arthritis Despite Ongoing Methotrexate Therapy
Rheumatoid Arthritis
Primary: Percentage of Participants Who Achieved American College of Rheumatology (ACR) 50 Response up to 24 Weeks — 18.1; 17.7; 17.0; 15.0 percentage of participants — p=0.059
Phase 3 N=604 MSB11456 in Participants With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Change From Baseline in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS28-ESR) — -3.53; -3.54 score on a scale
Phase 3 N=131 Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
Rheumatoid Arthritis
Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 70.8 percentage of participants
N/A N=76 Good EULAR Response In Patients With Early Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Primary: Participants With EULAR (Good) — 19 participants